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Purpose: To determine the extracellular matrix proteins involved in the formation of human granular and lattice type I
corneal stromal dystrophies, the expression patterns of fibrillin-2, tenascin-C, matrilin-2, and matrilin-4 were compared
in human corneal stromal dystrophy samples.
Methods: Ten cases of granular dystrophy, 7 cases of lattice dystrophy, and 6 normal corneal buttons collected during
corneal transplantation were examined for their expression patterns of fibrillin-2, tenascin-C, matrilin-2, and matrilin-4
by immunohistochemistry.
Results: Highly elevated fibrillin-2, tenascin-C, matrilin-2, and matrilin-4 were observed in the epithelial layer of both
granular and lattice type I dystrophies. Fibrillin-2, tenascin-C, and matrilin-4 in the granular dystrophy and all antibodies
in the lattice dystrophy showed statistically significant staining in the corneal stroma (p<0.05). Interestingly, fibrillin-2,
matrilin-2, and matrilin-4 stained significantly in amyloid plaques of lattice type 1 dystrophy.
Conclusions: Fibrillin-2, tenascin-C, matrilin-2, and matrilin-4 may be markers of the pathogenesis of either granular or
lattice type I corneal dystrophy, as revealed by immunohistochemical analysis. Each molecule seems to be involved in
the regeneration and reorganization of the corneal matrix in granular and lattice type I dystrophies.
Stromal corneal dystrophies are primary, genetically
determined, bilateral, noninflammatory disorders affecting
the stromal layer of the cornea. Granular type I corneal
dystrophy (corneal dystrophy Groenouw type I, OMIM
121900) is an autosomal-dominant disease characterized by
multiple stromal opacities [1]. Its onset usually occurs during
childhood, and the rate of clinical disease progression varies
between individuals. Lattice type I cornea dystrophy (Biber-
Haab-Dimmer dystrophy, OMIM 122200) has autosomal-
dominant inheritance and typically presents in the first decade
of life [1]. Both granular and lattice type I stromal dystrophies
have been linked to allelic mutations in the transforming
growth factor-β (TGF-β) induced gene-h3 (BIGH3) on
chromosome 5q31 [2-4]. The abnormal gene product (protein)
accumulates in the corneal layers and forms deposits that are
generally characteristic of the corneal dystrophy type [5].
The corneal stroma is composed of keratocytes (2%–3%
of the total stromal volume) [6], extracellular matrix (ECM)
molecules and stromal nerves. Corneal transparency and
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function are based on the special composition and assembly
of the extracellular matrix structures as well as on the cell-cell
and cell-ECM interactions [7]. Fibrillins play an important
role in maintaining tissue integrity and homeostasis through
the modulation of TGF-β and bone morphogenetic protein
signaling [8]. Fibrillin-2 binds to other ECM proteins, forming
microfibrils, and is mostly expressed during embryogenesis
[9]. Tenascin-C is a hexameric ECM glycoprotein, and its
expression is restricted to the fetal period of development
[10]. It is responsible for various dynamic cellular activities,
including cell adhesion [11], de-adhesion [12,13],
inflammation [10], tissue remodeling [10], angiogenesis
[14], migration [10], proliferation [15], and growth [11].
Enhanced expression of both fibrillin-2 and tenascin-C has
been observed in adults with fibroproliferative conditions,
such as wound healing and sclerosis [9,10,16]. Matrilin-2,
discovered by Deák et al. [17], is the largest member of an
extracellular matrix adaptor protein family of proteins that
contain von Willebrand factor A-like domains [18]. Matrilins
can connect to different types of collagenous and
noncollagenous ECM structures, participate in various
protein–protein interactions and, thus, determine the tissue
integrity [19]. Matrilin-4 is the most recently identified
member of the matrilin superfamily [20]. The trimer
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matrilin-4 is a component of dense and loose connective
tissues, bone, articular cartilage and nervous tissues and
associates with basement membranes [21].
To the best of our knowledge, this is the first study to
determine the expression pattern of fibrillin-2, tenascin-C,
matrilin-2, and matrilin-4 in these corneal stromal
dystrophies.
METHODS
Patients and tissue specimens: Tissue samples were obtained
from 12 patients who underwent penetrating keratoplasty.
Donor corneas obtained from the Cornea Bank Debrecen
(Department of Ophthalmology, University of Debrecen,
Medical and Health Science Centre) served as normal control
corneas. The study included 23 total cases: 10 cases of
granular type I dystrophy (7 patients), 7 cases of lattice type
I dystrophy (5 patients), and 6 corneal buttons (6 patients) with
a normal fibrillin-2, tenascin-C, matrilin-2, and matrilin-4
staining profile.
Antibodies: Monoclonal mouse antibodies against fibrillin-2
(clone 48; MAB2642, 1:250; Millipore, Bedford, MA) and
tenascin-C (DB7; ab86182, 1:50; Abcam, Cambridge, UK),
and polyclonal rabbit antibodies against matrilin-2
(ARP57667_P050, 1:300; Aviva Systems Biology, Corp., San
Diego, CA) and matrilin-4 (ab106379, 1:300; Abcam) were
used for immunohistochemistry.
Light microscopy: After corneal button removal, tissue
samples were immediately fixed in formalin (10%, pH 7.2)
and embedded in paraffin, and then 5−7 µm thick longitudinal
sections were cut (Leitz 1208 microtome; Wild Leitz, GmbH,
Wetzlar, Germany). Paraffin sections were mounted on
Superfrost Plus slides (Menzel-Gläser, Germany) and left to
dry overnight. Sections were deparaffinized with xylene and
rehydrated through a graded series of ethanol and distilled
water. For light microscopy analysis after rehydration, the
sections were stained with hematoxylin and eosin (H&E)
according to the manufacturer’s protocol and covered with
DPX (BDH Laboratory Supplies, Poole, England). Congo
Red staining was applied to show the presence of amyloid.
Analysis of staining: The histological morphology of the
corneal samples was evaluated by two independent
researchers (E.S., S.F.) at 20× magnification in routine
hematoxylin-eosin-stained and in Congo Red sections from
each individual cases.
Immunohistochemical staining: For immunohistochemical
analysis after rehydration, slides were treated with 3%
hydrogen peroxide to block the endogenous peroxidase
activity. For immunostaining, Histostain-Plus kits for mouse
and broad-spectrum primary antibodies (Invitrogen,
Camarillo, CA) were used. The sections were incubated in
serum-blocking solution for 30 min at room temperature.
Fibrillin-2, tenascin-C, matrilin-2, and matrilin-4 primary
antibodies were applied overnight at dilutions of 1:250, 1:50,
1:300, and 1:300, respectively, in TBS (pH 7.4) at 4 °C. Then,
the slices were washed twice with TBS, and the biotinylated
secondary antibody (1:200 dilution) was applied for 30 min
at room temperature. After washing with TBS, the samples
were treated with enzyme conjugate for 30 min at room
temperature. Reactions were visualized by the
diaminobenzidine (DAB) immunoperoxidase technique using
a DAB detection kit (Invitrogen). All kit solutions were
diluted in TBS, and the incubations for the DAB chromogen
procedure were performed in humid chambers at room
temperature according to the manufacturer’s protocol. Nuclei
were counterstained with Harris’ hematoxylin (Merck,
Darmstadt, Germany). The sections were dehydrated in a
graded series of ethanol and xylene and mounted with DPX
(BDH Laboratory Supplies). The slides were observed with a
light microscope (BX40; Olympus, Tokyo, Japan) equipped
with a digital camera (DP50; Olympus), and digitized images
were processed using Adobe Photoshop CS4 (Adobe Systems
Inc., CA).
We performed preabsorption reaction of matrilin-2
antibody using specific blocking peptide (Aviva Systems
Biology, San Diego). The lack of immunostaining in these
sections confirms the specificity of our antibody. This type of
negative control would be ideal and necessary in the
characterization and evaluation of antibodies used but it was
not possible to obtain the purified antigen from companies,
therefore control sections were stained in same way but the
primary antibody was omitted and replaced by non-immune
IgG (Sigma Aldrich, St. Louis, MO). No immunostaining was
observed in these sections indicating that our immunostaining
protocol is specific.
Immunofluorescence: To examine the colocalization of
matrilin-2 and fibrillin-2 in corneal epithelial cell double
immunostaining protocol has been performed. Tissue sections
were fixed as described above. To prevent the nonspecific
staining, before the antibody treatments the slides were
incubated in serum-blocking solution for 1 h at room
temperature. Subsequently, the slides were incubated with a
mixture of antibodies, that contained anti-matrilin-2 (diluted
1:250) and anti fibrillin-2 (diluted 1:300) antibodies. After 2
days long incubation at 4 °C with the primary antibody
solution the slides were rinsed in PBS and, the mixture of
secondary antibodies (Alexa Fluor 488 anti-mouse Ig and the
Alexa Fluor 546 anti-rabbit Ig; Invitrogen, Camarillo, CA) has
been placed to samples for 2 h at room temperature. The slides
were washed and the nuclei were stained using DAPI (4,6-
diamidino-2-fenilindole, dihydrocloride; 1:1,000; Molecular
Probes Camarillo, CA) in PBS containing 0.1% saponin for
30 min and covered with Vectashield mounting Media
(Vector Laboratories, Burlingame, CA). As negative controls
for each double label, the same procedure as above was
followed except that one of the primary antibodies was
omitted. No immunostaining was seen in these sections [22].
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Confocal microscopy: Acquired and presented images were
representative of all the samples examined with a Olympus
FV1000 confocal microscope (Olympus, Tokio, Japan).
Using 60× oil immersion lens single 1 µm thick section were
scanned. The confocal settings were identical for all scans and
kept constant during imaging. The recorded images were
processed by Adobe Photoshop CS4 software.
Computer-assisted image analysis: The immunostained
results were recorded as digital images using the setup
described above. From each immunohistochemical slide,
representative fields (100× objective) were captured. The
settings of the microscope and camera were kept constant
during capturing of the pictures, and digitalized images were
analyzed in Image J software with macroinstructions for
analyzing each captured area. The total intensity of DAB
developed immunohistochemical staining of different
antibodies used (Fibrillin-2/Tenascin-C/Matrilin-2 and-4),
was measured for each region of interest (ROI). Pictures were
recorded from 5 different randomly selected individual cases
in each groups and on 5 sections from each of them
independent gray intensity of ROIs (size approximately
5 μm2) was determined at two different locations of the corneal
epithelium (basal and suprabasal cell layers) and in the
subepithelial and deep zones of the corneal stroma.
Statistical analysis: Data were analyzed using the SPSS
software version 11.0.05 (SPSS Inc., Chicago, IL). Significant
differences in immunohistochemical staining intensity were
determined by the Mann–Whitney U-test; differences with
p<0.05 were considered significant.
RESULTS
Histopathology: Figure 1 shows the clinical appearance of
lattice type I (Figure 1A) and granular type I corneal dystrophy
(Figure 1B,C). Figure 1D shows longitudinally sectioned
granular type I stromal dystrophy after H&E staining. Typical
of granular type I stromal dystrophy, multiple eosinophilic
granules (asterisks) in the ground substance of the corneal
stroma were observed. Figure 1E shows the amyloid plaques
characteristic of lattice type I dystrophy. The deposits were
variable in size, located in the mid- to deep stroma. Figure 1F
shows the optical anisotropy of amyloids. Note the
characteristic yellow-green birefringence after Congo Red
staining under polarized light microscopy (arrowheads),
indicating that these structures are amyloid in nature. The
immunostainings of the anti-matrilin-2 and anti-fibrillin-2
antibodies were confirmed to localize in corneal epithelial
layer analyzed by a single laser scanning confocal microscopy
(Figure 1G-J).
Immunohistochemistry: The immunolocalization and staining
intensity of fibrillin-2, tenascin-C, matrilin-2, and matrilin-4
in normal, granular type I and lattice type I stromal dystrophy
corneas are summarized in Table 1.
Fibrillin-2—In normal corneal specimens, some corneal
epithelial cells showed moderate cytoplasmic
immunoreactivity (Figure 2A), although suprabasal and basal
epithelial expression was significantly weaker in normal
sections than in granular type I dystrophy (p<0.0001 for both;
Mann–Whitney U test) and in lattice type I corneal dystrophy
(p<0.0001 for both). The expression of fibrillin-2 in the basal
cell layer and the superficial squamous cell layer of the corneal
epithelium was intense in granular type I dystrophy (Figure
2B). No immunoreactivity was observed in Bowman’s
membrane. Stromal deposits showed intense
immunolocalization of fibrillin-2, but the ground substance of
the stroma between the granules did not stain with the
fibrillin-2 antibody (p<0.0001 for both). Nearly as intense
cytoplasmic immunoreactivity was found in the basal
epithelial cells in lattice type I dystrophy as in those of
granular type I dystrophy. Immunopositive cells formed a
relatively continuous border between the epithelium and
Bowman’s layer (Figure 2C). The anterior stroma and the
amyloid plaques showed definitive immunoreactivity for
fibrillin-2.
Tenascin-C—Normal corneal buttons showed mild
immunolocalization for tenascin-C in the corneal epithelium
(Figure 3A). In granular type I corneal dystrophy, epithelial
cells stained intensely for tenascin-C (p<0.0001 for both;
Figure 3B). Bowman’s membrane did not display any
immunopositivity for this protein. Stromal staining was
stronger and statistically significant in the stromal deposits
(p<0.0001 for both) compared with between the granules. In
basal epithelial cells, tenascin-C showed moderate
immunolocalization in lattice type I dystrophy (p<0.0001;
Figure 3C). In Bowman’s layer, immunoreactivity was absent.
Some mild immunostaining was detectable in the corneal
stroma, but the immunoreactivity found in the amyloid
deposits was absent or mild and, thus, nonspecific (p=0.912,
subepithelial).
Matrilin-2—Mild immunopositivity for matrilin-2 was
found in normal samples (Figure 4A). In granular type I
dystrophy, corneal epithelium showed intense, statistically
significant intracellular reactions for matrilin-2, especially in
wings and basal cells (p<0.0001 for both). Figure 4B shows
the focal thinning of Bowman’s layer in granular dystrophy.
Stromal expression of matrilin-2 was observed, mainly in the
corneal granules (p=0.248, subepithelial; p=0.190, deep). In
lattice type I corneal dystrophy cases, diffuse but intense
immunoreactivity for matrilin-2 was found in the enlarged
basal epithelial cells (p<0.0001; Figure 4C). The thinned or
absent Bowman’s membrane showed no immunostaining.
Corneal stroma in the amyloid deposits was mildly positive,
and posterior stroma showed mild to moderate
immunoreactivity in some lattice type I dystrophy cases, this
difference was statistically significant (p=0.0001).
Matrilin-4—In normal corneal specimens, mild
immunoreactivity was detected for matrilin-4 in corneal
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Figure 1. Granular and lattice type I dystrophies: biomicroscopic and histopathologic findings. The clinical appearance of lattice corneal
dystrophy (A). The branching dots and lines, representing amyloid deposits, are typical in the corneal stroma. Granular corneal dystrophy
under slit lamp and retroillumination (B). Well defined, white granules are present in the central corneal stroma (C). Histological section of
the granular type I corneal button (H&E) (D). The deposits are observed in the sub-Bowman layer in the stroma. The section of lattice corneal
dystrophy stains weak with Congo Red (E). Stromal fusiform amyloids stain with Congo red (F) and show birefringence under polarized light.
The colocalization of matrilin-2 and fibrillin-2 in normal corneal epithelium is presented in G-J. High magnification microphotos of single
laser scanning confocal optical sections (1 μm) demonstrating the immunolocalization of the anti-matrilin-2 (H, green) and anti-fibrillin-2
(I, red) antibody in corneal epithelial layer. The nuclei are blue on each images presented (G-J). Note that no nuclear staining is present on
the merged image (J) preclude the possibility of nonspecific reaction (internal control). Around the smaller DAPI labeled nucleus yellow color
may indicate the colocalization of these two antibodies used. Scale bars for light and polarized microscopic images are 100 μm, for confocal
images; 10 μm.
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epithelium (Figure 5A). In the epithelial layer of granular type
I dystrophy, diffuse, intense but discontinuous cytoplasmic
immunoreactivity for matrilin-4 was found (p<0.0001 for
both). Note the absence of Bowman’s membrane in Figure 5B.
Deposits in the corneal stroma were positive for matrilin-4,
and some stromal cells between the granules showed an
irregular and mild expression pattern (p<0.0001 for both). The
superficial and basal epithelial cells displayed statistically
significant, mild to moderate immunostaining for matrilin-4
in lattice type I dystrophy cases (p<0.0001 for both; Figure
5C). Bowman’s membrane, where present, was negative for
matrilin-4. The anterior and posterior third of corneal stroma
(p=0.945 and 0.101, respectively) and amyloid plaques
showed intense and statistically significant
immunolocalization of matrilin-4 in lattice type 1 dystrophy.
DISCUSSION
The present study investigated the expression patterns of
fibrillin-2, tenascin-C, matrilin-2, and matrilin-4 in granular
and lattice type I corneal stromal dystrophy samples.
Unexpectedly, significantly higher immunoreactivity was
detected for every antibody in the corneal epithelium in both
types of dystrophy compared to the normal control samples.
In the corneal stroma, stronger immunostaining for tenascin-
C was found in the granular type I dystrophy group than in the
control samples or lattice dystrophy group.
In granular type I corneal dystrophy, eosinophilic
deposits primarily accumulate in the corneal stroma as a result
of genetic mutation but also can be found in the epithelial layer
[23]. Accordingly, we observed moderate immunopositivity
for fibrillin-2 in the basal and superficial epithelial cells.
Fibrillins are produced by fibroblasts physiologically in
developing or in regenerating tissues. In granular dystrophy,
enhanced expression of fibrillin-2 can be explained by the
increased ECM production and the multiple functions of
fibrillins in ECM stabilization, in which they form
microfibrils that associate with basement membranes and
elastic fibers [24]. Additionally, modified BIGH3 proteins are
thought to promote the adhesion, migration, and proliferation
of epithelial cells and fibroblasts more efficiently than the wild
type [25-27]. Mutant BIGH3 protein–related peptides
contribute to amyloid formation by assembling β-sheet-rich
oligomeric structures in lattice type I dystrophy corneas [28].
In accord with other studies, we also demonstrated the
appearance of fibrillin-2 in amyloid plaques [29,30]. Basal
cells of the corneal epithelium, which secrete the epithelial
basement membrane, strongly expressed fibrillin-2 in lattice
type I dystrophy, suggesting an ongoing healing process or
fibrogenesis. In normal specimens, slight immunolocalization
for fibrillin-2 was occasionally observed in some epithelial
cells, which was significantly weaker than those in the
dystrophy samples. In addition, two papers have reported
immunopositivity for fibrillin-2 in the epithelial basement
membrane of normal buttons [29,31].
Epithelial erosions have been described both in granular
and in lattice type I dystrophy [32]. Increased expression of
fibrillin-2 in the corneal epithelial cells may indicate epithelial
Figure 2. Comparison of expression patterns of fibrillin-2 in healthy, granular type I and lattice type I stromal dystrophy corneal buttons, and
the colocalization of matrilin-2 and fibrillin-2 in corneal epithelium. Healthy samples showed mild immunolocalization in superficial and
basal epithelial layers (A). In addition to the strong epithelial immunopositivity of fibrillin-2 in granular dystrophy, marked labeling was
observed in stromal granules (B). In lattice corneal dystrophy, continuous cytoplasmic staining was found in the base of the basal columnar
cells (C). Scale bar 100 μm.
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wound healing. Brinckman et al. [16] attributed the co-
expression of fibrillin-2 and tenascin-C in wound healing to
altered cell adhesion in ECM. In our study, similar expression
patterns of fibrillin-2 and tenascin-C were found in granular
type I dystrophy but not in lattice dystrophy. We detected
stronger immunolocalization for tenascin-C in corneal
epithelial cells and stromal granules in granular type I
dystrophy specimens compared to the normal samples. This
finding supports our assumption of decreased cell adhesion as
a prominent feature of granular type I stromal dystrophy
corneas. Tenascin-C immunopositivity in inflammation [33],
active scarring [33,34], angiogenesis [35] and bullous
keratopathy [36,37] have been documented. In developmental
studies, tenascin-C is consistently detected in neonatal
corneas, but it is limited to the limbus in adults [38,39]. In
lattice type I dystrophy, moderate immunolocalization for
tenascin-C was observed in all epithelial layers. One
conspicuous finding of this study was the absent or weak
immunopositivity of tenascin-C in the amyloid deposits.
Similarly to other authors, we did not find this glycoprotein
in normal central corneas [31,33,40], although some
immunopositivity was observed in the epithelial cell layers. It
should be noted that we used the monoclonal antibody DB7
against tenascin-C [41] and that the tenascin-C variants have
different expression patterns [33,38].
Matrilins are recently identified adaptor proteins, but few
studies have investigated their presence and function in the
human cornea [31,39]. Matrilin-2, the non-collagenous
basement membrane component, colocalizes with
microfibrils and connects to fibrillin-2 [42]. In this study, mild
to moderate matrilin-2 expression was observed in the
epithelial layer and in the stromal deposits in granular type I
dystrophy, the expression patterns of fibrillin-2 and matrilin-2
were similar. This result also supports the notion that the
regeneration and reorganization of the ECM that occur in
granular type I dystrophy might be analogous to those of the
wound healing process. Matrilin-2 functions in early cell
differentiation during embryonal development, promotes
axonal growth and Schwann cell migration during peripheral
nerve regeneration [43], modulates wound healing in the skin
[44] and plays a role in tumor development [45,46].
We observed diffuse, marked immunoreactivity for
matrilin-2 in the epithelial cells of lattice type I dystrophy
samples, but only slight reactivity in the stromal amyloid
deposits. Posterior stroma also showed some mild
immunostaining for matrilin-2 in lattice stromal dystrophy.
Normal corneal epithelium and stroma exhibited mild
immunopositivity for matrilin-2; however, two previous
studies demonstrated immunolocalization of this oligomeric
protein in the epithelial basement membrane in adult corneas
[31,39]. Matrilin-4 staining in the stromal granules was less
pronounced in granular type I dystrophy than the matrilin-2
reactivity. In contrast, amyloid deposits showed stronger
immunolocalization for matrilin-4 than for matrilin-2 in
lattice type I dystrophy, highlighting the difference in
expression patterns between these two adaptor proteins in this
disease. However, matrilin-2 and −4 arise from a common
precursor, which suggests a close association between their
tissue localization and functional roles [21]. Matrilin-4 is
expressed in most tissue locations where any of the other
Figure 3. Comparison of the expression patterns of tenascin-C in healthy, granular type I, and lattice type I stromal dystrophy corneal buttons.
Cytoplasmic immunolabeling in normal sections was only observed in some basal epithelial cells (A). In granular dystrophy, diffuse, marked
immunostaining was recorded in the epithelial layers and in the stromal granules (B). Basal epithelium showed moderate immunostaining for
tenascin-C in lattice dystrophy (C). Scale bar 100 μm.
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matrilins are present [21]. Further studies focusing on the
difference between the roles of matrilin-2 and matrilin-4 are
necessary to explain their different expression patterns in
granular and lattice type I dystrophies. Matrilin-4
immunoreactivity has been observed in the epithelial
basement membrane in adult corneas [31,39], although we
only found weak immunostaining in the epithelial cells in
control specimens.
In conclusion, fibrillin-2 and tenascin-C are largely
restricted to developing fetal tissues but become expressed
again in granular type I corneal dystrophy and in lattice type
I dystrophy. Fibrillin-2, tenascin-C, matrilin-2, and matrilin-4
may be characteristic of the pathogenesis of either the granular
Figure 4. Comparison of the expression patterns of matrilin-2 in healthy, granular type I, and lattice type I stromal dystrophy corneal buttons.
In normal controls, matrilin-2 was present in most corneal epithelial layers (A). Intense epithelial immunopositivity was observed in granular
dystrophy. Focal thinning or loss of Bowman’s layer was also apparent (B). Enlarged immunopositive basal cells in corneal epithelium with
mild stromal staining were observed in lattice dystrophy (C). Scale bar 100 μm.
Figure 5. Comparison of the expression patterns of matrilin-4 in healthy, granular type I, and lattice type I stromal dystrophy corneal buttons.
Some immunolabeling was recorded in healthy corneal epithelium (A). In granular dystrophy, all epithelial layers were positive for matrilin-4,
and no Bowman’s layer was present under the epithelial basement membrane (B). Altered epithelial cell morphology in the basal layer was
observed, with strong basal immunolabeling for matrilin-4 in lattice type I dystrophy (C). Scale bar 100 μm.
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or lattice type I corneal dystrophy, as revealed by
immunohistochemical analysis. Each molecule seems to be
involved to some degree in the regeneration and
reorganization of the corneal matrix in granular and lattice
type I dystrophies. However, we observed substantial
differences in ECM reconstruction and remodeling between
the two dystrophy types. Further experiments are needed to
confirm the role of these proteins in the matrix regeneration
and repair in corneal stromal dystrophies and to reveal their
exact mechanism of action.
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